Mirum Pharmaceuticals Stock (NASDAQ:MIRM)
Previous Close
$42.09
52W Range
$23.14 - $48.89
50D Avg
$40.13
200D Avg
$33.33
Market Cap
$2.10B
Avg Vol (3M)
$379.93K
Beta
1.16
Div Yield
-
MIRM Company Profile
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
MIRM Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| KALV | KalVista Pharmaceuticals, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| IMCR | Immunocore Holdings plc |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| ARQT | Arcutis Biotherapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| ABOS | Acumen Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |